Compass Pathways (NASDAQ:CMPS) Price Target Raised to $22.00

Compass Pathways (NASDAQ:CMPS) had its target price raised by equities researchers at Royal Bank Of Canada from $21.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 100.13% from the company’s previous close.

A number of other research firms also recently commented on CMPS. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Compass Pathways in a report on Tuesday, April 28th. Canaccord Genuity Group cut their price objective on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th. BTIG Research restated a “buy” rating and set a $14.00 target price on shares of Compass Pathways in a report on Wednesday. Finally, Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average target price of $20.64.

Compass Pathways Trading Up 0.3%

Shares of CMPS traded up $0.03 during mid-day trading on Thursday, reaching $10.99. The company had a trading volume of 2,189,170 shares, compared to its average volume of 3,533,756. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -3.56 and a beta of 2.39. The firm has a fifty day simple moving average of $7.09 and a 200-day simple moving average of $6.69. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $11.28. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.55.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. On average, sell-side analysts anticipate that Compass Pathways will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CMPS. Toronto Dominion Bank boosted its stake in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in Compass Pathways during the third quarter valued at approximately $7,890,000. Nantahala Capital Management LLC raised its stake in Compass Pathways by 47.7% during the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Compass Pathways during the third quarter valued at approximately $6,926,000. Finally, Siren L.L.C. acquired a new stake in Compass Pathways during the fourth quarter valued at approximately $6,900,000. 46.19% of the stock is currently owned by institutional investors.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Compass Pathways reported first-quarter EPS of -$0.30, beating Wall Street estimates and suggesting better-than-expected operating performance. Earnings report and conference call
• Positive Sentiment: Management said regulatory progress continued for COMP360 in treatment-resistant depression, including an accelerated FDA review path, which is a key catalyst for the stock. Compass Pathways shares rise on Q1 results, accelerated FDA review
• Positive Sentiment: BTIG reaffirmed its Buy rating and raised its price target to $14, signaling continued analyst confidence in upside from current levels. BTIG rating update
• Neutral Sentiment: Multiple transcript and earnings-call recaps circulated after the release, reinforcing investor attention but not adding materially new information beyond the earnings update. Q1 2026 earnings call transcript

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.